Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

GR31L Anti-IGF-IR (Ab-3) Mouse mAb (33255.111)

Anti-IGF-IR (Ab-3) Mouse mAb (33255.111) MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: Anti-IGF-R, Anti-Insulin-Like Growth Factor Receptor

View Products on Sigmaaldrich.com
GR31L
  
Purchase on Sigma-Aldrich

Overview

Replacement Information

Key Spec Table

Species ReactivityHostAntibody Type
HMMonoclonal Antibody
Description
Overview

This product has been discontinued.



Recognizes the ~250-260 kDa IGF-1 receptor protein in MCF-7 cells. Does not cross-react with recombinant human IGF-I binding protein 1, IGF-I, or IGF-II.
Catalogue NumberGR31L
Brand Family Calbiochem®
SynonymsAnti-IGF-R, Anti-Insulin-Like Growth Factor Receptor
References
ReferencesLeroith, D., and Roberts, C. T., 2003. Cancer Letter 195, 127.
Dore, S., et al. 1997. Trends Neurosci. 20, 326.
Dore, S., et al. 1997. Proc. Natl. Acad. Sci. USA 94, 4772.
Walter, H.J., et al. 1997. Endocrinology 138, 3024.
Beilharz, E.J., et al. 1995. Mol. Brain Res. 29, 81.
Jones, J.I. and Clemmons, D.R. 1995. Endocr. Rev. 16, 3.
Product Information
FormLyophilized
FormulationLyophilized from PBS, 20 mM ammonium bicarbonate, ≤5% trehalose, 100 µg BSA.
Positive controlRecombinant IGF-I receptor protein or MCF7 cells
PreservativeNone
Quality LevelMQ100
Applications
Key Applications Enzyme-Linked Immunosorbent Assay
Immunoblotting (Western Blotting)
Neutralization Studies
Application NotesELISA (2 µg/ml, capture antibody)
Immunoblotting (non-denaturing protocols only)
Neutralization Studies (11 µg/ml, see comments)
Application CommentsEndotoxins: ≤1 EU/µg anti-IGF-IR. This antibody was selected for its ability to block cell surface IGF-I receptor mediated IGF-I and IGF-II bioactivities. The exact concentration of antibody required to neutralize the human cell surface IGF-I receptor mediated bioactivity is dependent on the IGF concentration as well as on the number and types of IGF receptors present on the cell surface (as a function of cell type and culture conditions). A concentration of 11 µg/ml neutralizes ~50-75% of IGF-I receptor-mediated rhIGF-I biological activity in MCF7 cells. This antibody recognizes a conformational epitope. The detection limit for human recombinant IGF-I receptor by immunoblotting is approximately 25 ng/lane. The detection limit for human recombinant IGF-I receptor is ~0.16 ng/well. Based on immunoblots and ELISA, this antibody does not cross-react with human recombinant IGF-I bp1, human recombinant IGF-I and human recombinant IGF-II. Antibody should be titrated for optimal results in individual systems.
Biological Information
Immunogenrecombinant, human, soluble IGF-I receptor
ImmunogenHuman
EpitopeExtracellular domain of IGF-I Receptor
Clone33255.111
HostMouse
IsotypeIgG₁
Species Reactivity
  • Human
Antibody TypeMonoclonal Antibody
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Harmful
Storage -20°C
Avoid freeze/thaw Avoid freeze/thaw
Do not freeze Ok to freeze
Special InstructionsReconstitute with sterile PBS to the desired concentration. Following reconstitution, antibody can be stored at 4°C for up to 1 month. For long-term storage, aliquot and freeze (-20°C).
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
GR31L 0

Documentation

Anti-IGF-IR (Ab-3) Mouse mAb (33255.111) SDS

Title

Safety Data Sheet (SDS) 

Anti-IGF-IR (Ab-3) Mouse mAb (33255.111) Certificates of Analysis

TitleLot Number
GR31L

References

Reference overview
Leroith, D., and Roberts, C. T., 2003. Cancer Letter 195, 127.
Dore, S., et al. 1997. Trends Neurosci. 20, 326.
Dore, S., et al. 1997. Proc. Natl. Acad. Sci. USA 94, 4772.
Walter, H.J., et al. 1997. Endocrinology 138, 3024.
Beilharz, E.J., et al. 1995. Mol. Brain Res. 29, 81.
Jones, J.I. and Clemmons, D.R. 1995. Endocr. Rev. 16, 3.

Citations

Title
  • Ruth L. Stephen, et al. (2001) Insulin-like growth factor receptor levels are regulated by cell density and by long term estrogen deprivation in MCF7 human breast cancer cells. Journal of Biological Chemistry 276, 40080-40086.
    		•
    Data Sheet

    Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

    Revision27-August-2007 RFH
    SynonymsAnti-IGF-R, Anti-Insulin-Like Growth Factor Receptor
    ApplicationELISA (2 µg/ml, capture antibody)
    Immunoblotting (non-denaturing protocols only)
    Neutralization Studies (11 µg/ml, see comments)
    DescriptionProtein G purified mouse monoclonal antibody. Recognizes the ~250-260 kDa IGF-1 receptor protein.
    BackgroundThe insulin growth factor (IGF) family, which includes IGF-I and IGF-II, binds to the IGF receptors (IGFRs) to mediate a number of biological effects. At least six IGF binding proteins (IGFBP-1-6) have also been identified which complex with the IGFs to modulate interactions with the receptors in either a stimulatory or inhibitory manner. Expression of these proteins is regulated during development, and is both tissue and cell specific. IGF-I exhibits potent effects on motor neuron survival, modulates neurotransmitter activity, and reduces apoptosis during normal development and axotomy. In addition, IGF-I serves a neuroprotective role against β-amyloid induced toxicity. It has also been demonstrated that IGF-I, IGF-II, and several IGFBPs are spatiotemporally regulated following hypoxic-ischaemic brain injuries.
    HostMouse
    Immunogen speciesHuman
    Immunogenrecombinant, human, soluble IGF-I receptor
    EpitopeExtracellular domain of IGF-I Receptor
    Clone33255.111
    IsotypeIgG₁
    Specieshuman
    Positive controlRecombinant IGF-I receptor protein or MCF7 cells
    FormLyophilized
    FormulationLyophilized from PBS, 20 mM ammonium bicarbonate, ≤5% trehalose, 100 µg BSA.
    PreservativeNone
    CommentsEndotoxins: ≤1 EU/µg anti-IGF-IR. This antibody was selected for its ability to block cell surface IGF-I receptor mediated IGF-I and IGF-II bioactivities. The exact concentration of antibody required to neutralize the human cell surface IGF-I receptor mediated bioactivity is dependent on the IGF concentration as well as on the number and types of IGF receptors present on the cell surface (as a function of cell type and culture conditions). A concentration of 11 µg/ml neutralizes ~50-75% of IGF-I receptor-mediated rhIGF-I biological activity in MCF7 cells. This antibody recognizes a conformational epitope. The detection limit for human recombinant IGF-I receptor by immunoblotting is approximately 25 ng/lane. The detection limit for human recombinant IGF-I receptor is ~0.16 ng/well. Based on immunoblots and ELISA, this antibody does not cross-react with human recombinant IGF-I bp1, human recombinant IGF-I and human recombinant IGF-II. Antibody should be titrated for optimal results in individual systems.
    Storage Avoid freeze/thaw
    -20°C
    Do Not Freeze Ok to freeze
    Special InstructionsReconstitute with sterile PBS to the desired concentration. Following reconstitution, antibody can be stored at 4°C for up to 1 month. For long-term storage, aliquot and freeze (-20°C).
    Toxicity Harmful
    ReferencesLeroith, D., and Roberts, C. T., 2003. Cancer Letter 195, 127.
    Dore, S., et al. 1997. Trends Neurosci. 20, 326.
    Dore, S., et al. 1997. Proc. Natl. Acad. Sci. USA 94, 4772.
    Walter, H.J., et al. 1997. Endocrinology 138, 3024.
    Beilharz, E.J., et al. 1995. Mol. Brain Res. 29, 81.
    Jones, J.I. and Clemmons, D.R. 1995. Endocr. Rev. 16, 3.
    Citation
  • Ruth L. Stephen, et al. (2001) Insulin-like growth factor receptor levels are regulated by cell density and by long term estrogen deprivation in MCF7 human breast cancer cells. Journal of Biological Chemistry 276, 40080-40086.
    		•